Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Denise Peterson

US Content Head, Pharma Insights

Washington, DC
Denise has had a colorful history reporting as a senior editor on numerous issues for publications now part of Informa's Pink Sheet and Scrip resources. Those include "The Pink Sheet", "The Blue Sheet" (NIH and public health programs), "The Beige Sheet" (medical technology reimbursement) and Medicare Drug Focus. Her areas of particular expertise include Capitol Hill and health care reimbursement. As US Content Head, she is inspired daily by the talented and knowledgeable US editorial team, and helps them provide the highest quality strategic insights for pharma's regulatory and commercial readers. She is based in Informa's flagship Washington, D.C. office.

Latest From Denise Peterson

Q4 Editor’s Picks: Clinical Trial Regulation

Coverage of clinical trial policy included commentary on rapid growth of the PD-1 pipeline by both US and China regulators; case studies and discussion of trial strategies including RWE, pediatric studies and decentralized trials; and US FDA commissioner-nominee Robert Califf’s R&D expertise.

Clinical Trials Real-World Evidence

Editor's Note: Please Help Pink Sheet Serve You Best

Please take our brief reader survey to help us better understand your content and delivery needs.

BioPharmaceutical

Editor’s Choice: Notable Pink Sheet Articles From Q3

A must-read selection of intriguing and popular articles posted in the Pink Sheet over the past three months.

Clinical Trials Market Access

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Reimbursement Advisory Committees

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps

Kite's CAR-T application seems to be sailing ahead without US FDA AdComm review; large employers in the US look into value-based contracting while European regulators band together on joint price negotiations; Teva is back at FDA with its EpiPen application. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Reimbursement Advisory Committees

Policy Prescriptions: User Fees, EMA Worries, PBM Strategies, PRIME Milestones

The US has plenty of new pharma legislation, Europe has plenty of worries about EMA's Brexit move, pharmacy benefit managers give plenty more scrutiny to which products earn a place on formulary. Policy Prescriptions rounds up recent regulatory news and trends reported by sister publication the Pink Sheet.

Drug Review Legislation
See All
UsernamePublicRestriction

Register